Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset

 
• By Joseph Haas

While Biogen is seeking to diversify its R&D efforts, unexpected good data in two forms of lupus make internally discovered BIIB059 a viable asset to take forward, although Phase III plans are not set.

Businessman running up stairway to the target, Challenge,
Developing a lupus drug is a steep climb for any company, but Biogen moved a step closer

More from Clinical Trials

More from R&D